Helicid (Omeprazole)

Helicid (omeprazole) is indicated for several acid‑related gastrointestinal conditions where reduction of gastric secretion is desired.

• Gastro‑oesophageal reflux disease (GERD) and associated heartburn
• Erosive oesophagitis confirmed by endoscopy
• Healing and maintenance therapy for peptic ulcer disease
• Part of combination regimens for Helicobacter pylori eradication
• Prevention of gastric ulcer recurrence in patients at risk

Side‑effects reported with Helicid are generally dose‑related and may vary from mild to severe; they are categorized below.

Common

• Headache
• Diarrhoea
• Nausea or abdominal discomfort

Serious

• Severe allergic reactions (anaphylaxis, angioedema)
• Clostridioides difficile‑associated colitis
• Low magnesium levels (hypomagnesemia) with prolonged use

Before starting Helicid, clinicians should consider several precautionary factors to ensure safe use.

• Assess renal and hepatic function, especially in patients with severe impairment
• Use the lowest effective dose for the shortest duration needed
• Evaluate for a history of hypersensitivity to omeprazole or other PPIs
• Monitor magnesium levels during long‑term therapy (>1 year)
• Consider alternative therapy in patients with known osteoporosis risk
• Use caution in pregnancy or lactation when benefit outweighs potential risk

Helicid may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Co‑administration with atazanavir or nelfinavir, which rely on gastric acidity for absorption
• Concurrent use with clopidogrel, which may reduce antiplatelet effectiveness
• Combination with high‑dose methotrexate, which can increase toxicity

Use with caution

• Drugs metabolized by CYP2C19 (e.g., diazepam, warfarin) may have altered plasma levels
• Antifungal agents such as ketoconazole or itraconazole, which need an acidic environment for absorption
• HIV protease inhibitors (e.g., lopinavir/ritonavir) where dose adjustments may be needed